Atlas Trials

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Clinical trial NCT03203642 · COMPLETED

Trial details

NCT number
NCT03203642
Sponsor
Kadmon, a Sanofi Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Autosomal Dominant Polycystic KidneyADPKD
Start date
2017-10-12
Primary completion
2022-01-25
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.